StockData
Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc. (CLDX) stock

CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$27.55−0.49 (-1.75%)

Close on Nov 18, 2026Market cap $2.16BP/E –Yield –

Celldex Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2025 it was $1.35M, down 80.3% from the year before. The highest annual figure on record is $12.04M in fiscal 2017.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.35M-80.3%
FY2024Dec 31, 2024$6.82M+3.6%
FY2023Dec 31, 2023$6.58M+191.7%
FY2022Dec 31, 2022$2.26M-50.4%
FY2021Dec 31, 2021$4.55M-36.9%
FY2020Dec 31, 2020$7.22M+107.8%
FY2019Dec 31, 2019$3.47M-60.7%
FY2018Dec 31, 2018$8.84M-26.6%
FY2017Dec 31, 2017$12.04M+132.2%
FY2016Dec 31, 2016$5.19M–

More Celldex Therapeutics figures

See a number that looks wrong?